🇺🇸 SODIUM PHOSPHATE P 32 in United States

FDA authorised SODIUM PHOSPHATE P 32 on 4 March 1959 · 4 US adverse-event reports

Marketing authorisations

FDA — authorised 4 March 1959

  • Application: NDA011777
  • Marketing authorisation holder: MALLINCKRODT
  • Local brand name: SODIUM PHOSPHATE P 32
  • Indication: SOLUTION — INJECTION, ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Leukaemia — 1 report (25%)
  2. Renal Failure — 1 report (25%)
  3. Respiratory Failure — 1 report (25%)
  4. Upper Respiratory Tract Infection — 1 report (25%)

Source database →

SODIUM PHOSPHATE P 32 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SODIUM PHOSPHATE P 32 approved in United States?

Yes. FDA authorised it on 4 March 1959; FDA has authorised it.

Who is the marketing authorisation holder for SODIUM PHOSPHATE P 32 in United States?

MALLINCKRODT holds the US marketing authorisation.